Cargando…

Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma

Uveal melanoma is the most common intraocular tumor in adults, representing approximately 5% of all melanoma cases. Up to 50% of uveal melanoma patients develop metastases that are resistant to most of the commonly used antineoplastic treatments. Virtually all uveal melanoma tumors harbor activating...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glinkina, Kseniya A., Teunisse, Amina F.A.S., Gelmi, Maria Chiara, de Vries, Jelle, Jager, Martine J., Jochemsen, Aart G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Articles: Basic Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470438/ https://www.ncbi.nlm.nih.gov/pubmed/37467061 http://dx.doi.org/10.1097/CMR.0000000000000911

Ejemplares similares

Preclinical Evaluation of Trabectedin in Combination With Targeted Inhibitors for Treatment of Metastatic Uveal Melanoma
por: Glinkina, Kseniya, et al.
Publicado: (2022)

Novel Treatments of Uveal Melanoma Identified with a Synthetic Lethal CRISPR/Cas9 Screen
por: Glinkina, Kseniya, et al.
Publicado: (2022)

Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin
por: Brouwer, Niels J., et al.
Publicado: (2021)

MDMX Regulates Transcriptional Activity of p53 and FOXO Proteins to Stimulate Proliferation of Melanoma Cells
por: Heijkants, Renier C., et al.
Publicado: (2022)

YAP/TAZ Activation Drives Uveal Melanoma Initiation and Progression
por: Li, Huapeng, et al.
Publicado: (2019)

Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma
por: Heijkants, Renier, et al.
Publicado: (2017)

HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target
por: Souri, Zahra, et al.
Publicado: (2019)

Expression of HDACs 1, 3 and 8 Is Upregulated in the Presence of Infiltrating Lymphocytes in Uveal Melanoma
por: Souri, Zahra, et al.
Publicado: (2021)

Differential Expression of DNA Repair Genes in Prognostically-Favorable versus Unfavorable Uveal Melanoma
por: Dogrusöz, Mehmet, et al.
Publicado: (2019)

Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies
por: Heijkants, R. C., et al.
Publicado: (2018)

Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target
por: Cao, Jinfeng, et al.
Publicado: (2018)

Patient-derived zebrafish xenografts of uveal melanoma reveal ferroptosis as a drug target
por: Groenewoud, Arwin, et al.
Publicado: (2023)

YAP as oncotarget in uveal melanoma
por: Yu, Fa-Xing, et al.
Publicado: (2014)

YAP and TAZ in Vascular Smooth Muscle Confer Protection Against Hypertensive Vasculopathy
por: Daoud, Fatima, et al.
Publicado: (2022)

HDAC Inhibition Increases HLA Class I Expression in Uveal Melanoma
por: Souri, Zahra, et al.
Publicado: (2020)

YAP/TAZ in Bone and Cartilage Biology
por: Zarka, Mylène, et al.
Publicado: (2022)

Zebrafish Patient-Derived Xenograft Model as a Preclinical Platform for Uveal Melanoma Drug Discovery
por: Yin, Jie, et al.
Publicado: (2023)

Loss of BAP1 Is Associated with Upregulation of the NFkB Pathway and Increased HLA Class I Expression in Uveal Melanoma
por: Souri, Zahra, et al.
Publicado: (2019)

Oncogenic functions of hMDMX in in vitro transformation of primary human fibroblasts and embryonic retinoblasts
por: Lenos, Kristiaan, et al.
Publicado: (2011)

MSK1 promotes cell proliferation and metastasis in uveal melanoma by phosphorylating CREB
por: Li, Jianchang, et al.
Publicado: (2019)

MITF in Normal Melanocytes, Cutaneous and Uveal Melanoma: A Delicate Balance
por: Gelmi, Maria Chiara, et al.
Publicado: (2022)

TAZ-CAMTA1 and YAP-TFE3 alter the TAZ/YAP transcriptome by recruiting the ATAC histone acetyltransferase complex
por: Merritt, Nicole, et al.
Publicado: (2021)

Pro-Invasive Activity of the Hippo Pathway Effectors YAP and TAZ in Cutaneous Melanoma
por: Nallet-Staub, Flore, et al.
Publicado: (2014)

DNA binding partners of YAP/TAZ
por: Kim, Min-Kyu, et al.
Publicado: (2018)

Hippo-YAP/TAZ signaling in angiogenesis
por: Park, Jeong Ae, et al.
Publicado: (2018)

YAP and TAZ regulate cell volume
por: Perez-Gonzalez, Nicolas A., et al.
Publicado: (2019)

Mechanisms of YAP/TAZ transcriptional control
por: Battilana, Giusy, et al.
Publicado: (2021)

YAP/TAZ dull the STING of aging
por: Francisco, Jamie, et al.
Publicado: (2022)

Nuclear Import and Export of YAP and TAZ
por: Kofler, Michael, et al.
Publicado: (2023)

YAP Activity is Not Associated with Survival of Uveal Melanoma Patients and Cell Lines
por: Kim, Yong Joon, et al.
Publicado: (2020)

Microphthalmia-Associated Transcription Factor: A Differentiation Marker in Uveal Melanoma
por: Gelmi, Maria Chiara, et al.
Publicado: (2023)

YAP1/TAZ drives ependymoma-like tumour formation in mice
por: Eder, Noreen, et al.
Publicado: (2020)

Clinical significance of YAP1 and TAZ in esophageal squamous cell carcinoma
por: Liu, Li, et al.
Publicado: (2021)

An optogenetic method for interrogating YAP1 and TAZ nuclear–cytoplasmic shuttling
por: Dowbaj, Anna M., et al.
Publicado: (2021)

WWTR1(TAZ)-CAMTA1 gene fusion is sufficient to dysregulate YAP/TAZ signaling and drive epithelioid hemangioendothelioma tumorigenesis
por: Seavey, Caleb N., et al.
Publicado: (2021)

TAZ and YAP are frequently activated oncoproteins in sarcomas
por: Fullenkamp, Colleen A., et al.
Publicado: (2016)

Multifaceted regulation and functions of YAP/TAZ in tumors
por: Liu, Huirong, et al.
Publicado: (2018)

YAP and TAZ are dispensable for physiological and malignant haematopoiesis
por: Donato, Elisa, et al.
Publicado: (2018)

The Role of YAP and TAZ in Angiogenesis and Vascular Mimicry
por: Azad, Taha, et al.
Publicado: (2019)

YAP and TAZ in Lung Development: The Timing Is Important
por: Warburton, David
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fljndv7s5ecaof538h3mpaf69h